InflaRx Shares Top $1 for 10 Days to Regain Nasdaq Compliance
InflaRx regained compliance with Nasdaq Listing Rule 5450(a)(1) after its ordinary shares closed at or above $1.00 for 10 consecutive business days from April 13 to April 24, 2026. The written notice from Nasdaq’s Listing Qualifications Department closes the bid price deficiency matter and safeguards the company’s continued listing status.
1. Nasdaq Compliance Restored
InflaRx regained compliance with Nasdaq Listing Rule 5450(a)(1) after its ordinary shares closed at or above $1.00 for ten consecutive business days from April 13 to April 24, 2026, prompting Nasdaq to close the bid price deficiency matter.
2. Implications for Listing and Liquidity
Restoring compliance eliminates the risk of delisting, ensures continued Nasdaq trading status, and supports share liquidity, potentially bolstering investor confidence in the company's market presence.
3. Company Pipeline and Focus
InflaRx specializes in anti-inflammatory therapeutics targeting the complement system, with lead programs izicopan for C5a receptor inhibition and vilobelimab, an anti-C5a monoclonal antibody in clinical development for inflammatory diseases.